Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies - PubMed (original) (raw)

Clinical Trial

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies

S M O'Reilly et al. Br J Cancer. 1993 Jun.

Free PMC article

Abstract

A trial of FAA and rIL-2 has been performed both to study the clinical efficacy of this combination and to determine whether they cause haemorrhagic necrosis by acting upon tumour vasculature. FAA and rIL-2 were given to 23 patients with progressing metastatic melanoma. FAA 4.8 gm m-2 was given as a 1 h infusion without urine alkalinisation on days 1, 8 and 15. rIL-2 (6-18 x 10(6) IU/m2/day) was given as a continuous infusion days 8-12 and 15-19 (nine patients) or days 8-12 only (14 patients). Treatment was repeated after 2 weeks unless there was disease progression. Of the 21 assessable patients there have been one complete (skin and liver) and two partial responses (skin and liver, skin and nodes) lasting 20 + 17 + and 15 months, overall response rate 14%. Unexpectedly severe hypotension after the third FAA, when given 2-4 days after RIL-2, was the major toxicity (8/15 grade 3 or 4). No alteration in coagulation parameters were seen during therapy of the first ten patients. No increase in tumour necrosis was seen in any of the 15 biopsies taken from ten patients after therapy. This suggests that FAA does not have similar vascular effects in human as it does in murine tumours.

PubMed Disclaimer

Cited by

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Lash CJ, et al. Br J Cancer. 1998 Aug;78(4):439-45. doi: 10.1038/bjc.1998.512. Br J Cancer. 1998. PMID: 9716024 Free PMC article.
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
Stratford MR, Rustin GJ, Dennis MF, Watfa RR, Howells N, O'Reilly SM. Stratford MR, et al. Br J Cancer. 1993 Jun;67(6):1351-5. doi: 10.1038/bjc.1993.250. Br J Cancer. 1993. PMID: 8512820 Free PMC article.
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
Haworth C, O'Reilly SM, Chu E, Rustin GJ, Feldmann M. Haworth C, et al. Br J Cancer. 1993 Jun;67(6):1346-50. doi: 10.1038/bjc.1993.249. Br J Cancer. 1993. PMID: 8512819 Free PMC article.
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
de Forni M, Chabot GG, Armand JP, Gouyette A, Klink-Alak M, Recondo G. de Forni M, et al. Cancer Chemother Pharmacol. 1995;35(3):219-24. doi: 10.1007/BF00686551. Cancer Chemother Pharmacol. 1995. PMID: 7805180 Clinical Trial.

References

1. Eur J Cancer Clin Oncol. 1987 Aug;23(8):1209-11 - PubMed
1. J Immunol. 1988 May 1;140(9):3261-5 - PubMed
1. Br J Cancer. 1989 Jul;60(1):104-6 - PubMed
1. Br J Cancer. 1990 Apr;61(4):618-21 - PubMed
1. Cancer Res. 1990 Sep 1;50(17):5537-42 - PubMed

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies - PubMed (original) (raw)